A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 Intramuscular Depot and Aricept® Oral Tablets (Pfizer Canada Inc.) in Healthy Male Volunteers is a PHASE1 clinical asset sponsored by G2GBio, Inc. in Alzheimer Disease. SEO and diligence focus: GB-5001, Placebo, Oral cohort, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.